Check for updates

OPEN ACCESS

EDITED BY Sara Baldelli, Università telematica San Raffaele, Italy

REVIEWED BY Donatella Verbanac, University of Zagreb, Croatia Marijana Lisak, Sisters of Charity Hospital, Croatia

*CORRESPONDENCE Yanqing Wu ⊠ wuyanqing01@sina.coms Ren Gong

⊠ gongren.student@sina.com RECEIVED 16 April 2024

ACCEPTED 01 October 2024 PUBLISHED 15 October 2024

CITATION

Wu Z, Yang W, Fang H, Chen Y, Wu Y and Gong R (2024) Exploring the association between dietary vitamin A and coronary artery disease risk in men and women: findings from a US population study. *Front. Nutr.* 11:1418159. doi: 10.3389/fnut.2024.1418159

COPYRIGHT

© 2024 Wu, Yang, Fang, Chen, Wu and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Exploring the association between dietary vitamin A and coronary artery disease risk in men and women: findings from a US population study

Zhijian Wu¹, Weichang Yang², Haiyang Fang¹, Yi Chen¹, Yanqing Wu^{1,3}* and Ren Gong¹*

¹Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ²Department of Respiratory Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ³Cardiovascular and Cerebrovascular Disease Hospital Affiliated with Nanchang University, Nanchang, China

Introduction: Coronary artery disease (CAD) is an important public health problem with negative impacts on individual health and socioeconomics. Studies on the relationship of dietary vitamin A (DVA) to CAD are limited and conflicting. The purpose of this study was to investigate the relationship between DVA and the prevalence of CAD in U.S. adults, with particular interest in sex differences.

Methods: Data from 26,449 NHANES participants were used for analysis. The association of DVA with the prevalence of CAD was investigated utilizing multivariate logistic regression models and fitted smoothed curves, and interaction tests were performed to explore potential modifiers.

Results: This study included 12,748 males and 13,701 females aged 50.34 ± 17.54 years. Overall, adjusted DVA was linearly negatively correlated with CAD (per natural ln (DVA) increment: OR 0.91, 95% CI 0.83–0.99). Multivariate regression analysis showed that among female participants, each natural increment of ln DVA was associated with a 22% reduction in CAD prevalence (OR 0.78, 95% CI 0.68–0.89). However, there was no significant correlation in male participants (*p* for interaction <0.001).

Conclusion: DVA was negatively associated with the prevalence of CAD, and further analysis revealed an interaction between DVA and sex in terms of CAD prevalence.

KEYWORDS

coronary artery disease, dietary vitamin A, sex-difference, cross-sectional study, interaction

1 Introduction

Individuals with coronary artery disease (CAD) are recognized as being at high or extremely high risk of developing adverse cardiovascular events in the future (1). The Global Burden of Disease International Collaborative Study published reports that CAD is the leading cause of death globally (2, 3). The number of deaths due to CAD is estimated to be 8.92 million globally, with an age-standardized mortality rate of 142/100,000, of which 173/100,000 are in the male population and 115/100,000 in the female population, with significant sex differences (2, 3). Besides revascularization, the treatment and prevention of CAD focuses on modifying cardiovascular risk factors, including lipid regulation to stabilize plaque, antiplatelet, control of blood pressure and blood glucose, and lifestyle improvements such as cessation of smoking and restriction of drinking, increase in physical activity, and improvement of dietary habits

(4). Although guidelines exist, there is a relative dearth of therapeutic recommendations for the management of CAD patients to reduce cardiovascular risk factors. Dietary recommendations for patients with CAD commonly call only for a low-salt, low-fat diet and usually lack recommendations for specific nutrient intake. The World Health Organization encourages the intake of a variety of vegetables and fruits for vitamin supplementation to prevent cardiovascular disease but cannot recommend specific vitamins and intakes owing to a lack of clinical evidence (5).

Vitamin A is an essential nutrient that can be derived from both animal and plant foods and has many roles in gene regulation, embryonic development, skin health, and normal vision. There is evidence that vitamin A is a protective factor against cardiovascular disease (CVD) and all-cause mortality (6). Additionally, studies have shown that plasma retinol levels in patients with coronary artery disease are significantly lower than in healthy subjects (7, 8). However, interestingly, an early study showed that the beta-carotene and retinoltreated group had a 17% higher overall mortality rate and a 26% higher mortality rate from cardiovascular causes compared to the placebo group (9). Another study showed that participants taking vitamin A had significantly higher lipid levels than those in the placebo group, and it is well-known that dyslipidemia plays an important role in CAD (10).

Given the limited and conflicting research on the relationship between vitamin A and CAD, the effect of vitamin A on CAD is vague. With the aim of filling this knowledge gap, this study analyzes data from the 2007–2018 National Health and Nutrition Examination Survey (NHANES) to evaluate the effect of dietary vitamin A (DDA) on the prevalence of CAD and to explore potential factors that might modify this effect.

2 Methods

2.1 Study design and population

The NHANES is a cross-sectional investigation conducted biennially with a complex multi-stage sampling design. This survey aims to provide health and nutritional information for a representative sample of the US public. Ethical approval for the NHANES research program was obtained from the Ethics Review Board of the National Center for Health Statistics (NCHS). All individuals provided written informed consent prior to participation. For more information, visit www.cdc.gov/nchs/nhanes/index.htm.

The present study explored sex-specific differences in the relationship between DVA and CAD among US adults using data from 6 survey cycles of NHANES between 2007 and 2018. Overall, 59,842 individuals were recruited in the above cycle. Exclusion criteria were as follows: those younger than 18 years (N=23,262), those who were in pregnancy (N=377), those with missing DVA data (N=8,282), and those with missing data on the history of CAD (N=1,441), DM (N=11), and HBP (N=20). Lastly, 26,449 individuals were included in the analyses (Figure 1).

2.2 Dietary vitamin A

The nutritional assessment component occupies a very critical place in NHANES, a 24-h dietary recall interview conducted with



participants of all ages by dietary interviewers who are professionally trained and fluent in Spanish and English. The first dietary recall interview was conducted instantly at the Mobile Examination Center (MEC), where subjects were interviewed about all food and beverage consumption within the past 24 h. The second interview was collected over the phone 3 to 10 days later. Standardized measurement tools were used to assist participants in accurately reporting the quantity and size of the food they consumed, followed by specialized software to calculate the total energy and nutrient intake of the foods. To provide a uniform measure of DVA, this study adopted the concept of retinol equivalents (RE), which is the amount of retinol corresponding to all vitamin A-active substances, such as retinol and β -carotene, as the intake of DVA. The total estimated value of DVA (μ g/d) in this study is the average of the two recall periods.

2.3 Coronary artery disease

Similar to the previous NHANES study, the health status questionnaire in NHANES was administered by trained health professionals and each question was standardized. Subjects were administered a questionnaire by a professional and questioned about the following: "Has a doctor or other health care professional ever told you that you have CAD?," "Has a doctor or other health care professional ever told you that you have angina pectoris?" and "Has a doctor or other health care provider ever told you about a heart attack? If their answer is "Yes" for at least one of the questions, they are assumed to have CAD (11, 12).

2.4 Potential covariates

Covariates that vary the DVK estimate of CAD over 10% or that are traditional risk factors for CAD were included in the final statistical analyses as potential confounders (13). After covariate screening, the following variables were used in the complete multivariate logistic regression analysis: Demographic data, including age, sex, race, educational attainment and poverty income ratio (PIR); dietary data for energy intake (kcal/d); examination data including body mass index (BMI, kg/m²), waist circumference (cm), and blood pressure (BP); laboratory data including alanine aminotransferase (ALT, U/L), serum creatinine (SCR, µmol/L), blood urea nitrogen (BUN, mg/dl), estimated glomerular filtration rate (eGFR, mL/ min/1.73 m²), uric acid (UA, µmol/L), fasting blood glucose (FBG, mmol/L), glycosylated hemoglobin (HBA1c, %), total cholesterol (TC, mmol/L), and triglyceride (mmol/L); and questionnaire data including history of smoking, alcohol consumption, as well as with or without hypertension and diabetes. Additionally, the equation used to calculate eGFR is based on the modification of diet in the renal disease study group [MDRD, eGFR = 186 × (SCR × 0.011312) ^ (- 1.154) × age ^ (- $(0.203) \times (\text{female} \times 0.762)$ (14). Hypertension was defined as a selfreported diagnosis of hypertension by a healthcare practitioner, or systolic BP \geq 140 mmHg and/or diastolic BP \geq 90 mmHg (15). Diabetes was defined as a self-reported diagnosis of diabetes by a healthcare practitioner, or FBG \geq 7 mmol/L, or HbA1c >6.5 (16).

2.5 Statistical analysis

Since DVA is skewed, this study log-transforms it with a constant e as the base (In DVA) and then uses it for statistical analysis. Furthermore, it was grouped according to the DVA tertiles. To compare the baseline characteristics between groups, continuous data were analyzed by one-way ANOVA and categorical variables by chi-squared test or Fisher's exact test. Continuous data were expressed as mean±standard deviation or median (interquartile range), and categorical data were expressed as count (%). To assess the association of DVA with the prevalence of CAD, three multivariate regression models were constructed. In Model 1, no adjustment was made for any variables; in Model 2, demographic data including age, sex (only for all participants), race, education, and PIR were adjusted; in Model 3, BMI, waist circumference, smoking and drinking history, hypertension, diabetes, TC, triglycerides, UA, SCR, eGFR, BUN, ALT, and energy were adjusted additionally to the factors adjusted in Model 2. Using generalized additive modeling and smoothed curve fitting (penalized spline method) to visualize the shape of the association of DVA and CAD. Additionally, the potential effects of the following variables on the relationship between DVA and CAD were evaluated: age (<50 vs. 50-65 vs. >65 years), race (Mexican American vs. other Hispanic vs. non-Hispanic White vs. non-Hispanic Black vs. other race), educational attainment (<9th grade vs. 9-11th grade vs. high school vs. college vs. graduate and above), BMI (<25 vs. 25-30 vs. >30 kg/m²), smoking status (never vs. quit vs. current), alcohol consumption (never vs. 1-5 drinks/month vs. 5-10 drinks/month vs. >10 drinks/month vs. unknown), and eGFR (<60 vs. ≥60 mL/ min/1.73 m²), hypertension (yes vs. no), diabetes (yes vs. no).

Missing values for variables were handled using the scientific method: continuous variables were interpolated using multiple

interpolations, while categorical variables were handled by adding dummy variables [20.12% (N=5,323) were missing for the history of drinking]. Generally, missing data were low (<10%) for all variables except drinking history. Comparisons of the supplemented data with the original data are shown in Supplementary Table S1. Statistical analyses were performed using the R package (version 4.2.1) and EmpowerStats (http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA). A two-tailed p<0.05 was set for statistical significance.

3 Results

3.1 Study subjects' baseline characteristics

Table 1 shows the baseline characteristics of the participants after grouping according to sex and DVA tertiles. Overall, there were 26,449 participants in this study, including 12,748 males and 13,701 females, with an age (mean \pm standard deviation) of 50.34 \pm 17.54 years. The prevalence of CAD was 7.53% (*N*=1,991), generally consistent with the US Disease Survey (17), and the median DVA of participants was 506.5 µg/d (interquartile range 314.5–777.5 µg/d). Specifically, the prevalence of CAD and the median DVA for males were 9.84% and 536 µg/d (interquartile range 330.5–828.5 µg/d), respectively, whereas for females they were 5.37% and 480 µg/d (interquartile range 301.0–731.5 µg/d), respectively.

In male participants, compared to the low DVA population, the moderate to high DVA population were usually older, non-Hispanic White, and non-smokers had higher levels of educational attainment, PIR, BUN, and energy intake, had lower levels of BMI, waist circumference, HbA1c, FBG, eGFR, UA, and TC, and did not have CAD. Among female participants, compared with the low DVA population, those with moderate to high DVA tended to be older, non-Hispanic white, never-smokers, and drinkers; to have higher levels of education, PIR, BUN, TC, and energy intake; to have lower values of BMI, waist circumference, HbA1c, FBG, eGFR, and UA; and to be free of CAD and diabetes. However, there were no significant differences in the history of hypertension, ALT, SCR, and triglyceride levels among the three groups of male and female subjects. Moreover, no significant differences were found in the history of diabetes and alcohol consumption among the male subjects in the three study groups.

3.2 DVA and CAD prevalence association

Table 2 summarises the analysis of the association of DVA with CAD using multivariate regression, and Figure 2 characterizes the shape of the relationship after adjustment. Overall, adjusted DVA was linearly negatively correlated with CAD (per natural ln (DVA) increment: OR 0.91, 95% CI 0.83–0.99, p=0.026). Furthermore, after converting the continuous DVA to tertiles of DVA, the ORs of adjusted tertile 2 (376.5–666.0, µg/d) and tertile 3 (666.5–23582.0 µg/d) were 0.91 (95% CI 0.79–1.05) and 0.83 (95% CI 0.71–0.97), respectively, compared to tertile 1 (0.0–376.0, µg/d). Generalized additive model and smoothed curve fitting showed that DVA and CAD prevalence were negatively correlated in female participants, but not in males (Figure 3). This is consistent with the results of multivariate regression analyses, in which the ORs for the

TABLE 1 Baseline characteristics of study participants.

Characteristics ^{a,b}	Males (N = 12,748) Diatery vitamin A (µg/d) tertiles			<i>p</i> -value	F	Females (<i>N</i> = 13,701)				
					Diater					
	Tertiles 1	Tertiles 2	Tertiles 3		Tertiles 1	Tertiles 2	Tertiles 3			
DVA range	0.0-396.0	396.5-710.5	711.0-23582.0		0.0-359.0	359.5-630.0	630.5-10475.5			
Ν	4,248	4,250	4,250		4,561	4,568	4,572			
Age, years	48.56±17.25	51.06 ± 17.78	51.54 ± 17.88	<0.001	48.87±17.10	50.32 ± 17.39	51.98±17.62	< 0.001		
Race, %				<0.001				< 0.001		
Mexican American	715 (16.83%)	617 (14.52%)	472 (11.11%)		723 (15.85%)	727 (15.92%)	537 (11.75%)			
Other Hispanic	454 (10.69%)	398 (9.36%)	342 (8.05%)		558 (12.23%)	510 (11.16%)	430 (9.41%)			
Non-Hispanic White	1,457 (34.30%)	1,895 (44.59%)	2,241 (52.73%)		1,571 (34.44%)	1,956 (42.82%)	2,243 (49.06%)			
Non-Hispanic Black	1,135 (26.72%)	861 (20.26%)	723 (17.01%)		1,260 (27.63%)	914 (20.01%)	849 (18.57%)			
Other race	487 (11.46%)	479 (11.27%)	472 (11.11%)		449 (9.84%)	461 (10.09%)	513 (11.22%)			
Education level, %				< 0.001				< 0.001		
<9th grade	576 (13.56%)	375 (8.82%)	265 (6.24%)		504 (11.05%)	429 (9.39%)	301 (6.58%)			
9–11th grade	739 (17.40%)	576 (13.55%)	467 (10.99%)		740 (16.22%)	570 (12.48%)	468 (10.24%)			
High school	1,122 (26.41%)	1,013 (23.84%)	923 (21.72%)		1,122 (24.60%)	1,024 (22.42%)	885 (19.36%)			
College	1,088 (25.61%)	1,194 (28.09%)	1,246 (29.32%)		1,431 (31.37%)	1,481 (32.42%)	1,498 (32.76%)			
Graduate or above	723 (17.02%)	1,092 (25.69%)	1,349 (31.74%)		764 (16.75%)	1,064 (23.29%)	1,420 (31.06%)			
PIR	2.29 ± 1.55	2.69±1.63	2.86±1.65	<0.001	2.16 ± 1.54	2.51±1.62	2.72±1.65	< 0.001		
Smoking status, %				<0.001				< 0.001		
Never smoking	1,833 (43.15%)	1,964 (46.21%)	2,117 (49.81%)		2,761 (60.53%)	2,932 (64.19%)	3,113 (68.09%)			
Quit smoking	1,098 (25.85%)	1,267 (29.81%)	1,301 (30.61%)		691 (15.15%)	859 (18.80%)	877 (19.18%)			
Current smoking	1,317 (31.00%)	1,019 (23.98%)	832 (19.58%)		1,109 (24.31%)	777 (17.01%)	582 (12.73%)			
Drinking status, %				0.30				0.011		
Never drinking	565 (13.30%)	534 (12.56%)	578 (13.60%)		1,470 (32.23%)	1,388 (30.39%)	1,422 (31.10%)			
1-5 drinks/month	1,851 (43.57%)	1,878 (44.19%)	1,868 (43.95%)		1,596 (34.99%)	1,704 (37.30%)	1,631 (35.67%)			
5-10 drinks/month	355 (8.36%)	314 (7.39%)	353 (8.31%)		207 (4.54%)	210 (4.60%)	212 (4.64%)			
10+ drinks/month	660 (15.54%)	715 (16.82%)	642 (15.11%)		283 (6.20%)	320 (7.01%)	367 (8.03%)			
Unknown	817 (19.23%)	809 (19.04%)	809 (19.04%)		1,005 (22.03%)	946 (20.71%)	940 (20.56%)			
BMI, kg/m ²	29.02±6.30	29.20 ± 6.08	28.55 ± 6.08	< 0.001	30.36 ± 7.74	29.95±7.82	29.16±7.53	< 0.001		

Wu et al.

TABLE1 (Continued)

glomerular filtration rate; UA, uric acid; TC, total cholesterol.

^aMissing treatment: categorical variables (adding dummy variables), continuous variables (multiple interpolations). ^bData are presented as mean±standard deviation, median (interquartile range), or numbers (%) as appropriate.

Characteristics ^{a,b}	Males (N = 12,748)			<i>p</i> -value	F	<i>p</i> -value		
Diatery vitamin A (μ g/d) tertiles) tertiles	Diater					
	Tertiles 1	Tertiles 2	Tertiles 3		Tertiles 1	Tertiles 2	Tertiles 3	
Waist circumference, cm	101.58 ± 16.23	102.69 ± 15.78	101.16±15.76	<0.001	98.88 ± 16.87	98.34 ± 16.78	96.77±16.61	<0.001
Hypertension, %				0.210				0.257
No	2,409 (56.71%)	2,292 (53.93%)	2,409 (56.68%)		2,542 (55.73%)	2,624 (57.44%)	2,587 (56.58%)	
Yes	1,839 (43.29%)	1,958 (46.07%)	1,841 (43.32%)		2,019 (44.27%)	1,944 (42.56%)	1,985 (43.42%)	
Diabetes, %				0.206				0.005
No	3,312 (77.97%)	3,333 (78.42%)	3,379 (79.51%)		3,628 (79.54%)	3,690 (80.78%)	3,760 (82.24%)	
Yes	936 (22.03%)	917 (21.58%)	871 (20.49%)		933 (20.46%)	878 (19.22%)	812 (17.76%)	
CAD				0.007				0.001
No	3,864 (90.96%)	3,783 (89.01%)	3,846 (90.49%)		4,270 (93.62%)	4,342 (95.05%)	4,353 (95.21%)	
Yes	384 (9.04%)	467 (10.99%)	404 (9.51%)		291 (6.38%)	226 (4.95%)	219 (4.79%)	
HBA1c, %	5.86 ± 1.19	5.81 ± 1.06	5.79 ± 1.07	0.019	5.79 ± 1.13	5.75 ± 1.02	5.73 ± 0.97	0.017
FBG, mmol/L	5.91 ± 2.40	5.81 ± 2.12	5.79 ± 2.17	0.046	5.65 ± 2.15	5.65 ± 2.18	5.53 ± 1.91	0.012
ALT, U/L	24.00 (18.00-33.00)	24.00 (19.00-33.00)	24.00 (18.00-32.00)	0.326	17.00 (14.00-23.00)	18.00 (15.00-23.00)	18.00 (15.00-24.00)	0.071
SCR, µmol/	91.89±55.30	90.99 ± 37.24	90.31±38.05	0.267	70.79 ± 37.14	69.37±31.82	70.02 ± 36.36	0.159
BUN, mg/dL	4.94 ± 2.09	5.28 ± 2.18	5.43±2.16	<0.001	4.56 ± 2.25	4.73 ± 2.06	4.91±2.12	<0.001
eGFR, mL/min/1.73 m ²	91.35 ± 25.54	89.88 ± 26.42	89.51±23.35	0.003	94.98 ± 29.21	94.98 ± 28.32	92.84 ± 27.08	< 0.001
UA, μmol/L	369.09±80.29	363.60±78.67	352.93±77.68	<0.001	296.20±80.65	290.78±76.88	289.00±76.87	<0.001
TC, mmol/L	4.93±1.11	4.90 ± 1.11	4.85 ± 1.08	0.002	5.05 ± 1.09	5.06 ± 1.05	5.11 ± 1.05	0.021
Triglyceride, mmol/L	1.49 (0.97-2.34)	1.50 (1.00-2.35)	1.47 (0.96–2.28)	0.166	1.29 (0.87–1.90)	1.29 (0.88–1.94)	1.28 (0.86–1.92)	0.646
Energy, kcal/d	1907.29±724.16	2279.66±732.29	2703.21±982.94	<0.001	1456.29±529.74	1772.91±562.70	2009.13±663.56	<0.001

DVA, dietary vitamin A; PIR, poverty income ratio; BMI, body mass index; CAD, coronary artery disease; HbA1c, hemoglobin A1c; FPG, fasting plasma glucose; ALT, alanine aminotransferase; SCR, serum creatinine; BUN, blood urea nitrogen; eGFR, estimated

TABLE 2 Relative odds of CAD according to DVA in different models among US adults.

Dietary vitamin A, µg/d	Event (%)	Coronary artery disease OR (95% CI), <i>p</i> -value						
		Model 1	Model 2	Model 3				
All participants		N = 26,449	24,174	22,248				
Continuous (ln DVA)	1,991 (7.53%)	0.95 (0.89, 1.01) 0.074	0.83 (0.78, 0.89) <0.001	0.91 (0.83, 0.99) 0.026				
Tertile 1 (0.0–376.0)	669 (7.6%)	Reference	Reference	Reference				
Tertile 2 (376.5–666)	684 (7.75%)	1.03 (0.92, 1.15) 0.623	0.85 (0.75, 0.96) 0.011	0.91 (0.79, 1.05) 0.217				
Tertile 3 (666.5–23582.0)	638 (7.23%)	0.95 (0.85, 1.06) 0.356	0.70 (0.61, 0.80) <0.001	0.83 (0.71, 0.97) 0.017				
p for trend		0.056	<0.001	0.017				
Males		N = 12,748	11,660	10,802				
Continuous (ln DVA)	1,255 (9.84%)	1.06 (0.98, 1.14) 0.162	0.92 (0.84, 1.00) 0.058	1.01 (0.90, 1.13) 0.897				
Tertile 1 (0.0–396.0)	384 (9.04%)	Reference	Reference	Reference				
Tertile 2 (396.5–710.5)	467 (10.99%)	1.24 (1.08, 1.43) 0.003	1.01 (0.86, 1.19) 0.863	1.03 (0.85, 1.22) 0.790				
Tertile 3 (711.0–23582.0)	404 (9.51%)	1.04 (0.90, 1.21) 0.560	0.80 (0.67, 0.94) 0.009	0.92 (0.75, 1.13) 0.416				
p for trend		0.666	0.001	0.224				
Females		N = 13,701	12,514	11,446				
Continuous (ln DVA)	736 (5.37%)	0.79 (0.72, 0.87) <0.001	0.72 (0.65, 0.80) <0.001	0.78 (0.68, 0.89) <0.001				
Tertile 1 (0.0–359.0)	291 (6.38%)	Reference	Reference	Reference				
Tertile 2 (359.5–630.0)	226 (4.95%)	0.79 (0.66, 0.94) 0.003	0.69 (0.57, 0.85) <0.001	0.82 (0.66, 1.01) 0.065				
Tertile 3 (630.5–10475.5)	219 (4.79%)	0.74 (0.62, 0.88) 0.001	0.65 (0.54, 0.80) <0.001	0.79 (0.60, 1.00) 0.051				
p for trend		<0.001	<0.001	0.025				
<i>p</i> value for interaction*		<0.001	<0.001	< 0.001				

Values are ORs (95% CIs) unless otherwise indicated. CAD, coronary artery disease; DVA, dietary vitamin A; In DVA value was log *e*-transformed. Model 1 was adjusted for none. Model 2 was adjusted for age, sex (only for the overall population), race, education levels, and PIR. Model 3 was adjusted for age, sex (only for the overall population), race, education levels, and PIR. Model 3 was adjusted for age, sex (only for the overall population), race, education levels, and PIR. Model 3 was adjusted for age, sex (only for the overall population), race, education levels, PIR, BMI, waist circumference, smoking and drinking history, hypertension, diabetes, TC, triglycerides, UA, SCR, eGFR, BUN, ALT, and energy. **p* value for the interaction test: the two-way interaction of sex and Ln DVA (continuous) on CAD.

association between DVA and CAD prevalence among female participants were remarkably stable (OR 0.79, 95% CI 0.72–0.87, OR 0.72, 95% CI 0.65–0.80, and OR 0.78, 95% CI 0.68–0.89 in Models 1, 2, and 3, respectively), and the trend tests were all statistically significant. However, among male participants, ORs were unstable and not statistically significant across models. Reanalysis of the interpolated data still yielded consistent results: among female participants, the fully adjusted pooled ORs for the relationship of DVA as continuous and tertile values with CAD were 0.79 (95% CI 0.68–0.91) and 0.79 (95% CI 0.62–1.00), respectively; however, among male participants, DVA was not significantly associated with CAD either as a continuous or a tertile value (Supplementary Tables S2, S3). Sex was able to modify the relationship between DVA and CAD prevalence (*p* for interaction <0.001).

3.3 Subgroup analysis

This study performed stratified analyses in male and female participants to assess the association of DVA with CAD prevalence in separate subgroups. In the whole population, we found that age significantly modified the relationship between DVA and CAD prevalence (p for interaction=0.019), with a significant negative correlation between DVA and CAD in those <50 years of age and a neutral relationship in those >65 years of age. Similar findings were found for female participants but not for males. Other variables including race, education, smoking history, drinking history, hypertension, diabetes, and eGFR did not significantly alter the



and blue line represent the estimated values and their corresponding 95% confidence intervals, respectively. Adjustment factors included age, sex, race, education levels, PIR, BMI, waist circumference, smoking and drinking history, hypertension, diabetes, TC, triglycerides, UA, SCR, eGFR, BUN, ALT, and energy.

relationship between DVA and CAD prevalence in the entire population (Supplementary Figure S1), male participants (Figure 4A), or female participants (Figure 4B) (*p* for all interactions >0.05).

4 Discussion

Our large cross-sectional study, based on NHANES data between 2007 and 2018, found that DVA reduced the prevalence of CAD. Further analyses showed that appropriately increasing daily vitamin A intake only reduced the prevalence of CAD in the female population, while no such relationship was observed in the male population. In addition, this was the first study to assess sex differences in the relationship between DVA and CAD.



FIGURE 3

Association between DVA and the prevalence of CAD by sex. The solid line and dashed line represent the estimated values in males and females, respectively. The adjustment factors included age, sex, race, education levels, PIR, BMI, waist circumference, smoking and drinking history, hypertension, diabetes, TC, triglycerides, UA, SCR, eGFR, BUN, ALT, and energy.

Previous studies have not evaluated the relation of DVA to the prevalence of CAD, and the majority of studies have observed an association of plasma vitamin A levels with CAD and its related conditions. An early case-control study involving 82 participants suggests that increased concentrations of vitamins A and E are independently related to a reduced risk of CAD in white South African men (18). Basnet et al. (19) also found vitamin A to be one of the important nutritional factors in CAD. Similarly, Matos et al. (20) found a correlation between vitamin A status and the severity of CAD. In addition, a large cohort study reported that adequate nutritional intake of vitamin A was associated with reduced all-cause or CVD mortality (21). However, an early multicenter, randomized, double-blind, placebocontrolled primary prevention trial involving 18,314 smokers, ex-smokers, and lime-exposed workers showed no benefit from additional supplementation with carotenoids and vitamin A and may have had a detrimental impact on the incidence of lung cancer and cardiovascular disease, as well as on all-cause mortality (9). Subsequently, to account for the increase in cardiovascular mortality, further analysis of the data on serum lipids from the study revealed that the mean cholesterol concentration in the group with additional carotenoid and vitamin A supplementation was 5.3 mg/dL (0.137 mmoL/L) above that of the placebo group (10). Taken together, the results of these studies are limited in addressing the relationship between vitamin A and CAD, and the relationship between DVA and CAD remains unclear.

Examining previous studies, this large-scale cross-sectional study we conducted is the first to assess the association of DVA with the prevalence of CAD among U.S. adults, filling a gap in the area and bringing some new findings. First, this study found that DVA was a protective factor for CAD: the prevalence of CAD gradually decreased with increasing DVA intake. Although the pathological mechanisms are unclear, they seem physiologically plausible. Atherosclerosis is a systemic inflammatory disease resulting in lipid deposition in the arterial wall due to endothelial dysfunction caused by a chronic inflammatory response (22). Oxidative stress is an important part of this process (23, 24).

A						В					
Subgroup	N	Events n(%)		HR (95% CI)	P for interaction	Subgroup	N	Events n(%)		HR (95% CI)	P for interaction
All participants	12748	1255				All participants	13701	736 (5.37%)			
Age, years					0.398	Age, years		,			0.062
< 50	6339	107 (1.69%)	+	1.27 (0.93, 1.72)		< 50	6925	90 (1.30%)		0.64 (0.5, 0.81)	
50~65	3423	384 (11.22%)		1.02 (0.85, 1.22)		50~65	3690	250 (6.78%)		0.79 (0.65, 0.96)	
>65	2986	764 (25.59%)	_ _	1.01 (0.86, 1.18)		>65	3086	396 (12.83%)		0.91 (0.76, 1.09)	
Race				1.01 (0.00) 1110/	0.947	Race	0000	000 (12:00 /0)		0.01 (0.10) 1.00)	0.58
Mexican American	1804	109 (6.04%)		1.03 (0.66, 1.61)	0.0.11	Mexican American	1987	75 (3.77%)		- 1.11 (0.62, 1.99)	0.00
Other Hispanic	1194	100 (8.38%)		1.09 (0.65, 1.82)		Other Hispanic	1498	73 (4.87%)		1 (0.55, 1.8)	
Non-Hispanic White	5593	770 (13.77%)		0.97 (0.8, 1.18)		Non-Hispanic White	5770	393 (6.81%)	_	0.72 (0.56, 0.92)	
Non-Hispanic Black	2719	200 (7.36%)		1.11 (0.84, 1.47)		Non-Hispanic Black	3023	150 (4.96%)		0.79 (0.57, 1.09)	
Other race	1438	76 (5.29%)		0.94 (0.56, 1.59)		Other race	1423	45 (3.16%)		- 0.97 (0.49, 1.92)	
Education level, %		(,		0.34 (0.00, 1.03)	0.409	Education level, %	1420	40 (0.1070)		0.37 (0.43, 1.32)	0.42
<9th grade	1216	183 (15.05%)		0.96 (0.7, 1.32)	0.403	<9th grade	1234	90 (7.29%)		0.75 (0.48, 1.17)	0.42
9-11th grade	1782	184 (10.33%)		1.22 (0.88, 1.68)		9–11th grade	1778	151 (8.49%)		0.61 (0.43, 0.86)	
High school	3058	303 (9.91%)		1.25 (0.94, 1.66)		High school	3031	213 (7.03%)		0.93 (0.67, 1.29)	
College	3528	327 (9.27%)		1.01 (0.77, 1.34)		College	4410	215 (7.03%) 215 (4.88%)		0.86 (0.63, 1.18)	
Graduate or above	3164	258 (8.15%)	- 1								
Drinking status, %	5104	200 (0.1070)		0.86 (0.61, 1.19)	0.074	Graduate or above	3248	67 (2.06%)		0.97 (0.56, 1.68)	0 500
Never Drinking	1677	168 (10.02%)		0.00 (0.07.4.47)	0.871	Drinking status, %	1000	005 (0.000()			0.503
1-5 drinks/month	5597	588 (10.51)		0.99 (0.67, 1.47)		Never Drinking	4280	285 (6.66%)		0.84 (0.63, 1.11)	
5–10 drinks/month	1023	55 (5.38%)		1.03 (0.85, 1.25)		1-5 drinks/month	4931	257 (5.21%)		0.81 (0.62, 1.07)	
10+ drinks/month	2017	179 (8.87%)				5-10 drinks/month	629	14 (2.23%)		0.58 (0.1, 2.51)	
Unknown	2434	265 (10.8%)		1.16 (0.8, 1.69)		10+ drinks/month	970	37 (3.81%)		0.41 (0.19, 0.87)	
Smoking Status, %	2434	203 (10.0%)		0.97 (0.71, 1.32)		Unknown	2891	143 (4.95%)		0.83 (0.56, 1.23)	
Never Smoking	5914	381 (6.44%)			0.133	Smoking Status, %					0.994
Quit Smoking	3666	597 (16.28%)	_	0.97 (0.76, 1.25)		Never Smoking	8806	358 (4.07%)		0.82 (0.64, 1.04)	
				0.96 (0.77, 1.19)		Quit Smoking	2427	212 (8.74%)		0.81 (0.58, 1.14)	
Current Smoking	3168	277 (8.74%)		1.3 (1.02, 1.67)		Current Smoking	2468	166 (6.73%)		0.8 (0.58, 1.1)	
Hypertension d, %	50.13	000 (47 000()			0.561	Hypertension d, %					0.773
Yes	5647	960 (17.03%)		1.06 (0.91, 1.23)		Yes	5948	617 (10.37%)		0.8 (0.67, 0.96)	
No	7110	295 (4.15%)		0.97 (0.76, 1.24)		No	7753	119 (1.53%)		0.76 (0.55, 1.06)	
Diabetes e, %					0.709	Diabetes e, %					0.347
Yes	2724	551 (20.23%)	-+	1 (0.82, 1.22)		Yes	2623	326 (12.43%)		0.85 (0.67, 1.09)	
No	10024	704 (7.02%)		1.05 (0.88, 1.26)		No	11078	410 (3.70%)		0.73 (0.59, 0.9)	
BMI, kg/m2					0.117	BMI, kg/m2					0.448
<25	3377	244 (7.23%)		1.12 (0.88, 1.43)		<25	3973	149 (3.75%)		0.69 (0.54, 0.87)	
25~30	4748	439 (9.25%)		0.84 (0.69, 1.03)		25~30	3832	201 (5.26%)		0.83 (0.66, 1.04)	
>=25	4485	542 (12.08%)		1.06 (0.9, 1.24)		>=25	5766	372 (6.45%)		0.8 (0.68, 0.95)	
eGFR, mL/min/1.73 m2					0.429	eGFR, mL/min/1.73 m2	2100	2. 2 (0.4070)		2.5 (0.00) 0.00)	0.243
<60	1090	303 (27.80%)		0.93 (0.7, 1.24)	0.420	<60	1169	212 (18,14%)		0.93 (0.67, 1.28)	0.240
>=60	11065	895 (8.09%)		1.06 (0.91, 1.23)		>=60	11820	895 (4.13%)		0.74 (0.62, 0.89)	
			0.5 1.0 1.5 2.0				11820	895 (4.13%)		20 25 0.74 (0.62, 0.69)	

FIGURE 4

Stratified analyses by potential modifiers of the association between DVA and the prevalence of CAD by sex*. (A) Males and (B) females. *Each subgroup analysis was adjusted for age, race, education levels, PIR, BMI, waist circumference, smoking and drinking history, hypertension, diabetes, TC, triglycerides, UA, SCR, eGFR, BUN, ALT, and energy. Except for the stratifying variable.

Vitamin A is a fat-soluble vitamin consisting of 3 active forms (retinol, retinaldehyde, and retinoic acid) with strong antioxidant properties (25). An intervention study that included 46 participants showed that vitamin A supplementation for 4 months could reduce inflammatory cytokine IL-17 production and gene expression of the major transcription factor controlling T-helper cells (Th17 cells) differentiation (26). In a similar study, Sezavar et al. (27) found that vitamin A supplementation inhibited T helper cells (Th1 cells) activity in both atherosclerotic and healthy participants. In addition, vitamin A is thought to be involved in ameliorating cardiovascular disease risk factors, including improving blood pressure, improving blood glucose lipid metabolism, reducing LDL oxidation, and inhibiting smooth muscle cell activity (28). Although the above findings appear encouraging, they are limited by sample size and population characteristics, so further long-term clinical studies are justified and necessary.

Second, the findings indicated that there was a significant interaction between sex and DVA, and sex could modify the association of DVA with CAD (p for interaction <0.001). Higher intake of vitamin A was associated with a lower prevalence of CAD in female participants, which was not the case in male participants. This discrepancy seems to be accounted for by sex hormone differences between men and women. Studies have shown that the incidence of cardiovascular disease in women is significantly lower than in men of similar age, and the risk of cardiovascular disease is higher in women with hyperandrogenemia (29-31). A study suggests that a diet rich in green lutein-carotenoid vegetables reduces the incidence of CAD in women, but not in men (32). Furthermore, retinoic acid is one of the most active forms of vitamin A. It plays an important role in cell growth, differentiation, and embryonic development processes (33). The production of retinoic acid begins with the metabolite of vitamin A, retinol, which is converted to retinaldehyde by the alcohol dehydrogenase family of enzymes, but this step is reversible (34, 35). The cytoplasmic aldehyde dehydrogenase 1 (ALDH1) family of enzymes catalyzes the oxidation of retinaldehyde to retinoic acid, completing this irreversible final step (35, 36). Evidence suggests that Aldh 1 activation levels, expression levels in different tissues, and effects on retinoic acid are regulated by sex hormones (37, 38). In animal models of atherosclerosis constructed through diet, males formed atherosclerotic plaques earlier and more broadly than females, and independent of lipid status (39, 40). The above results may be explained by the direct action of sex hormones within the vascular wall and the effect on cardiovascular risk factors. In addition, we note that age may be able to modify the relationship between DVA and CAD in female participants, which may also be due to the fact that younger women benefit from the protective effects of estrogen on the cardiovascular system, whereas after menopause, estrogen depletion leads to a higher risk of developing CAD (41). On the other hand, nutritional deficiencies continued to be a severe public health problem among women of childbearing age (15–49 years) (42). It has been reported in recent years that about one-third of women of childbearing age globally suffer from varying degrees of nutritional deficiencies (43). This deficiency affects maternal metabolism and tissue proliferation and hurts fetal growth and development (44). An epidemiological study showed that the prevalence of vitamin A deficiency in African women of childbearing age ranged from 4 to 22 percent (45). Therefore, an appropriate increase in vitamin A intake may be more beneficial to women. Furthermore, women consumed more vitamin A from vegetable sources and less from animals compared to men (46). Sex differences in the source of DVA may impact CAD development. Further, differences in lifestyle habits may also contribute to this outcome, with males more likely to be smokers and drinkers. Studies have shown that ethanol can compete with retinol for ethanol dehydrogenase, which catalyses the oxidation of retinol to retinaldehyde, which is then further oxidized to retinoic acid (47). In additional, studies have shown that the body converts beta-carotene to vitamin A at a maximum of 50 percent efficiently. Non-smokers, women and underweight people absorb the most beta-carotene, while smokers and alcohol drinkers absorb the least (48). However, more studies are necessary to validate our views and further explore their underlying mechanisms.

This study also has some limitations, which necessitates a welldesigned large prospective study to validate the findings. Firstly, this study is a cross-sectional research design and the influence of unknown or unmeasured confounding factors (e.g., other nutritional factors, environmental exposures, etc.) on the results cannot be completely ruled out, nor can causal inferences be made. Secondly, we used dietary intake and outcome variable data obtained based on questionnaires, which might be prone to recall bias and measuring errors. Nevertheless, it is worth noting that questionnaires play a major role in national surveys of health and nutrition, and many highquality studies have been performed on the basis of questionnaire data. In addition, caution is needed when extrapolating this result to other geographic areas due to geographic differences.

5 Conclusion

DVA was negatively associated with the prevalence of CAD, suggesting a protective effect of DDA against CAD. Further analysis revealed an interaction between DVA and sex in terms of CAD prevalence: in women, higher DVA was associated with a lower prevalence of CAD, whereas in men the two were not significantly correlated.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by NCHS Ethics Review Board (ERB) Approval: Protocol #2018-01, Protocol #2011-17, Protocol #2005-06, and Protocol #98-12. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

ZW: Conceptualization, Data curation, Investigation, Methodology, Software, Writing – original draft, Writing – review & editing. WY: Conceptualization, Software, Writing – original draft. HF: Methodology, Supervision, Writing – original draft. YC: Conceptualization, Methodology, Software, Writing – review & editing. YW: Conceptualization, Funding acquisition, Methodology, Writing – review & editing. RG: Conceptualization, Methodology, Software, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by grants from Jiangxi Provincial Key R&D Program, Grant No. 20212BBG71004, and Jiangxi Provincial Health Commission Key Science and Technology Innovation Projects, Grant No. 2024ZD007.

Acknowledgments

The authors would like to give special thanks to the NHANES 2003–2018 researchers, participants, and those who worked behind the scenes, as their contributions made it possible to complete this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Hong SJ, Lee YJ, Lee SJ, Hong BK, Kang WC, Lee JY, et al. Treat-to-target or highintensity statin in patients with coronary artery disease: a randomized clinical trial. *JAMA*. (2023) 329:1078–87. doi: 10.1001/jama.2023.2487

2. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sexspecific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* (2018) 392:1736–88. doi: 10.1016/S0140-6736(18)32203-7

3. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* (2018) 392:1789–858. doi: 10.1016/S0140-6736(18)32279-7

4. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. (2023) 82:833–955. doi: 10.1016/j.jacc.2023.04.003

5. World Health Organization. (2007). Prevention of cardiovascular disease guidelines for assessment and management of cardiovascular risk, (Switzerland, Geneva: WHO Press).

6. Brazionis L, Walker KZ, Itsiopoulos C, O'Dea K. Plasma retinol: a novel marker for cardiovascular disease mortality in Australian adults. *Nutr Metab Cardiovasc Dis.* (2012) 22:914–20. doi: 10.1016/j.numecd.2011.08.009

7. Cebi A, Kaya Y, Gungor H, Demir H, Yoruk IH, Soylemez N, et al. Trace elements, heavy metals, and vitamin levels in patients with coronary artery disease. *Int J Med Sci.* (2011) 8:456–60. doi: 10.7150/ijms.8.456

8. Rock E, Winklhofer-Roob BM, Ribalta J, Scotter M, Vasson MP, Brtko J, et al. Vitamin A, vitamin E and carotenoid status and metabolism during aging: functional and nutritional consequences (VITAGE PROJECT). *Nutr Metab Cardiovasc Dis.* (2001) 11:70–3.

9. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med.* (1996) 334:1150–5. doi: 10.1056/NEJM199605023341802

10. Cartmel B, Dziura J, Cullen MR, Vegso S, Omenn GS, Goodman GE, et al. Changes in cholesterol and triglyceride concentrations in the Vanguard population of the Carotene and Retinol Efficacy Trial (CARET). *Eur J Clin Nutr.* (2005) 59:1173–80. doi: 10.1038/sj.ejcn.1602229

11. Wu Z, Yang W, Li M, Li F, Gong R, Wu Y. Relationship between dietary decanoic acid and coronary artery disease: a population-based cross-sectional study. *Nutrients.* (2023) 15:4308. doi: 10.3390/nu15204308

12. Skipina TM, Patel N, Upadhya B, Soliman EZ. Cannabis use is associated with prevalent coronary artery disease. *Am J Med Sci.* (2022) 364:304–8. doi: 10.1016/j. amjms.2022.04.005

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2024.1418159/ full#supplementary-material

SUPPLEMENTARY FIGURE S1

Stratified analyses by potential modifiers of the association between DVA and the prevalence of CAD for whole participants*. *Each subgroup analysis was adjusted for sex, age, race, education levels, PIR, BMI, waist circumference, smoking and drinking history, hypertension, diabetes, TC, triglycerides, UA, SCR, eGFR, BUN, ALT, and energy. Except for the stratifying variable.

13. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. (1989) 79:340–9. doi: 10.2105/AJPH.79.3.340

14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med.* (1999) 130:461–70. doi: 10.7326/0003-4819-130-6-199903160-00002

15. Vidal-Petiot E. Thresholds for hypertension definition, treatment initiation, and treatment targets: recent guidelines at a glance. *Circulation*. (2022) 146:805–7. doi: 10.1161/CIRCULATIONAHA.121.055177

16. American Diabetes Association. 2. Classification and diagnosis of diabetes: *Standards of Medical Care in Diabetes-2021. Diabetes Care.* (2021) 44:S15–33. doi: 10.2337/dc21-S002

17. Centers for Disease Control and Prevention (CDC). Prevalence of coronary heart disease—United States, 2006–2010. MMWR Morb Mortal Wkly Rep. (2011) 60:1377–81.

18. Delport R, Ubbink JB, Human JA, Becker PJ, Myburgh DP, Vermaak WJ. Antioxidant vitamins and coronary artery disease risk in South African males. *Clin Chim Acta*. (1998) 278:55–60. doi: 10.1016/S0009-8981(98)00131-4

19. Basnet TB, Srijana GC, Basnet R, Neupane B. Dietary nutrients of relative importance associated with coronary artery disease: public health implication from random forest analysis. *PLoS One.* (2020) 15:e0243063. doi: 10.1371/journal.pone.0243063

20. Matos A, Gonçalves V, Souza G, Cruz S, Cruz S, Ramalho A. Vitamin A nutritional status in patients with coronary artery disease and its correlation with the severity of the disease. *Nutr Hosp.* (2018) 35:1215–20. doi: 10.20960/nh.1804

21. Chen F, Du M, Blumberg JB, Ho CK, Ruan M, Rogers G, et al. Association among dietary supplement use, nutrient intake, and mortality among U.S. adults: a cohort study. *Ann Intern Med.* (2019) 170:604–13. doi: 10.7326/M18-2478

22. Tall AR, Yvan-Charvet L. Cholesterol, inflammation, and innate immunity. Nat Rev Immunol. (2015) 15:104–16. doi: 10.1038/nri3793

23. Batty M, Bennett MR, Yu E. The role of oxidative stress in atherosclerosis. *Cells*. (2022) 11:11. doi: 10.3390/cells11233843

24. Shaito A, Aramouni K, Assaf R, Parenti A, Orekhov A, Yazbi AE, et al. Oxidative stress-induced endothelial dysfunction in cardiovascular diseases. *Front Biosci.* (2022) 27:105. doi: 10.31083/j.fbl2703105

25. Riccioni G, Bucciarelli T, Mancini B, Corradi F, Di Ilio C, Mattei PA, et al. Antioxidant vitamin supplementation in cardiovascular diseases. Ann Clin Lab Sci. (2007) 37:89–95.

26. Mottaghi A, Ebrahimof S, Angoorani P, Saboor-Yaraghi AA. Vitamin A supplementation reduces IL-17 and RORc gene expression in atherosclerotic patients. *Scand J Immunol.* (2014) 80:151–7. doi: 10.1111/sji.12190

27. Sezavar H, Saboor-Yaraghi AA, Salehi E, Mottaghi A. Whether vitamin a supplementation is effective in T-bet and IFN-y gene expression reduction? *Immunol Investig.* (2015) 44:189–98. doi: 10.3109/08820139.2014.953635

28. Ciccone MM, Cortese F, Gesualdo M, Carbonara S, Zito A, Ricci G, et al. Dietary intake of carotenoids and their antioxidant and anti-inflammatory effects in cardiovascular care. *Mediat Inflamm*. (2013) 2013:782137. doi: 10.1155/2013/782137

29. Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. *Nat Rev Cardiol.* (2009) 6:532–42. doi: 10.1038/nrcardio.2009.105

30. Liu Y, Ding J, Bush TL, Longenecker JC, Nieto FJ, Golden SH, et al. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. *Am J Epidemiol.* (2001) 154:489–94. doi: 10.1093/aje/154.6.489

31. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. *Ann Intern Med.* (1976) 85:447–52. doi: 10.7326/0003-4819-85-4-447

32. Bhupathiraju SN, Wedick NM, Pan A, Manson JE, Rexrode KM, Willett WC, et al. Quantity and variety in fruit and vegetable intake and risk of coronary heart disease. *Am J Clin Nutr.* (2013) 98:1514–23. doi: 10.3945/ajcn.113.066381

33. Cunningham TJ, Duester G. Mechanisms of retinoic acid signaling and its roles in organ and limb development. *Nat Rev Mol Cell Biol.* (2015) 16:110–23. doi: 10.1038/nrm3932

34. Billings SE, Pierzchalski K, Butler TNE, Pang XY, Trainor PA, Kane MA, et al. The retinaldehyde reductase DHRS3 is essential for preventing the formation of excess retinoic acid during embryonic development. *FASEB J.* (2013) 27:4877–89. doi: 10.1096/ fj.13-227967

35. Kumar S, Sandell LL, Trainor PA, Koentgen F, Duester G. Alcohol and aldehyde dehydrogenases: retinoid metabolic effects in mouse knockout models. *Biochim Biophys Acta*. (2012) 1821:198–205. doi: 10.1016/j.bbalip.2011.04.004

36. Duester G. Retinoic acid synthesis and signaling during early organogenesis. *Cell.* (2008) 134:921–31. doi: 10.1016/j.cell.2008.09.002

37. Yasmeen R, Reichert B, Deiuliis J, Yang F, Lynch A, Meyers J, et al. Autocrine function of aldehyde dehydrogenase 1 as a determinant of diet- and sex-specific differences in visceral adiposity. *Diabetes*. (2013) 62:124–36. doi: 10.2337/db11-1779

38. Wang X, Sperkova Z, Napoli JL. Analysis of mouse retinal dehydrogenase type 2 promoter and expression. *Genomics*. (2001) 74:245–50. doi: 10.1006/geno.2001.6546

39. von Dehn G, von Dehn O, Völker W, Langer C, Weinbauer GF, Behre HM, et al. Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. *Horm Metab Res.* (2001) 33:110–4. doi: 10.1055/s-2001-12405

40. Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C, et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. *Arterioscler Thromb Vasc Biol.* (1997) 17:2192–9. doi: 10.1161/01.ATV.17.10.2192

41. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. *N Engl J Med.* (1999) 340:1801–11. doi: 10.1056/NEJM199906103402306

42. Arthur SS, Nyide B, Soura AB, Kahn K, Weston M, Sankoh O. Tackling malnutrition: a systematic review of 15-year research evidence from INDEPTH health and demographic surveillance systems. *Glob Health Action*. (2015) 8:28298. doi: 10.3402/gha.v8.28298

43. WHO. Global nutrition policy review 2016–2017: country progress in creating enabling policy environments for promoting healthy diets and nutrition. Geneva, Switzerland: World Health Organization (2018).

44. Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett TJ. Vitamin profile of 563 gravidas during trimesters of pregnancy. *J Am Coll Nutr.* (2002) 21:33–7. doi: 10.1080/07315724.2002.10719191

45. Harika R, Faber M, Samuel F, Kimiywe J, Mulugeta A, Eilander A. Micronutrient status and dietary intake of Iron, vitamin a, iodine, folate, and zinc in women of reproductive age and pregnant women in Ethiopia, Kenya, Nigeria and South Africa: a systematic review of data from 2005 to 2015. *Nutrients*. (2017) 9:1096. doi: 10.3390/nu9101096

46. Hallfrisch J, Muller DC, Singh VN. Vitamin A and E intakes and plasma concentrations of retinol, beta-carotene, and alpha-tocopherol in men and women of the Baltimore Longitudinal Study of Aging. *Am J Clin Nutr.* (1994) 60:176–82. doi: 10.1093/ajcn/60.2.176

47. Russell RM. The vitamin A spectrum: from deficiency to toxicity. *Am J Clin Nutr.* (2000) 71:878–84. doi: 10.1093/ajcn/71.4.878

48. Dawson MI. The importance of vitamin A in nutrition. *Curr Pharm Des.* (2000) 6:311–25. doi: 10.2174/1381612003401190